- Home
- IMG vs CYCN Comparison
IMG vs CYCN Comparison
Compare IMG & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMG
- CYCN
- Stock Information
- Founded
- IMG 2011
- CYCN 2018
- Country
- IMG United States
- CYCN United States
- Employees
- IMG N/A
- CYCN N/A
- Industry
- IMG
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- IMG
- CYCN Health Care
- Exchange
- IMG NYSE
- CYCN Nasdaq
- Market Cap
- IMG 7.2M
- CYCN 6.5M
- IPO Year
- IMG 2020
- CYCN N/A
- Fundamental
- Price
- IMG $0.66
- CYCN $3.01
- Analyst Decision
- IMG
- CYCN
- Analyst Count
- IMG 0
- CYCN 0
- Target Price
- IMG N/A
- CYCN N/A
- AVG Volume (30 Days)
- IMG 639.9K
- CYCN 12.7K
- Earning Date
- IMG 05-27-2025
- CYCN 05-06-2025
- Dividend Yield
- IMG N/A
- CYCN N/A
- EPS Growth
- IMG N/A
- CYCN N/A
- EPS
- IMG N/A
- CYCN N/A
- Revenue
- IMG $3,785,663.00
- CYCN $2,000,000.00
- Revenue This Year
- IMG $99.05
- CYCN N/A
- Revenue Next Year
- IMG $130.30
- CYCN N/A
- P/E Ratio
- IMG N/A
- CYCN N/A
- Revenue Growth
- IMG 109.62
- CYCN N/A
- 52 Week Low
- IMG $0.25
- CYCN $1.27
- 52 Week High
- IMG $8.00
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- IMG N/A
- CYCN 61.70
- Support Level
- IMG N/A
- CYCN $2.44
- Resistance Level
- IMG N/A
- CYCN $2.75
- Average True Range (ATR)
- IMG 0.00
- CYCN 0.19
- MACD
- IMG 0.00
- CYCN 0.06
- Stochastic Oscillator
- IMG 0.00
- CYCN 95.31
About IMG CIMG INC
CIMG Inc is a coffee and technologies company. The company is a co-packer of single-serve pour-over coffee, coffee brew bags and Dripkits. The company's brand portfolio includes Coffee Blenders, Twin Peaks, Active Cup, Relax Cup, Think Cup, Nude Cup, Pine Ranch Coffee, and Dripkit. Its geographical segments are North America, which accounts for the majority of revenue; and South Korea.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.